血清IL-6、IL-18及IFN-γ检测与宫颈癌的相关性研究
摘要
目的：探讨宫颈癌患者血清IL-6、IL-18及IFN-γ水平的变化,为临床上诊断宫颈癌及对其预后判断寻求可靠的实验室依据。
方法：本研究采用夹心酶联免疫吸附法测定18例正常人、38例宫颈上皮内瘤变(CIN)患者及49例宫颈癌患者血清中IL-6、IL-18及IFN-γ的水平。
结果：
1、正常组、CIN组及宫颈癌组中IL-6的水平分别为13.42±2.14pg／ml、25.25±4.19pg／ml、57.15±13.22pg／ml,其中宫颈癌组IL-6的水平高于CIN及正常组(p<0.05),CIN组也高于正常组(p<0.05).在宫颈癌的不同临床期别中,IL-6的水平呈现出上升的趋势,IL-6的水平是随的宫颈癌临床期别的升高而增加的,Ⅱb期59±13.22pg／ml>Ⅱa期55.15±15.92pg／ml>Ⅰa期42.15±11.42 pg／ml
2、正常组、CIN组及宫颈癌组中IL-18的水平分别为569.83±97.29 pg／ml、381.63±62.54pg／ml、252.65±52.81pg／ml,其中宫颈癌组IL-18的水平低于CIN及正常组(p<0.05),CIN组也低于正常组(p<0.05).IL-18的水平则随着临床期别的升高而下降,Ⅰa期(628.84±89.62 pg／ml)>Ⅰb期(539.81±78.19)>Ⅱa期(424.84±71.92)>Ⅱa期(424.84±71.92)Ⅱb期(424.84±71.92
3、正常组、CIN组及宫颈癌组中IFN-γ的水平分别为67.73±26.71pg／ml、23.94±15.74pg／ml、7.62±3.23pg／ml,其中宫颈癌组IFN-γ的水平明显低于正常组(p<0.01),CIN组也低于正常组(p<0.05),IFN-γ水平随着临床期别的升高,水平也有下降的趋势,Ⅰa期(12.81±4.03 pg／ml)>Ⅰb期(9.32±3.83pg／ml)>Ⅱa期(8.82±2.93 pg／ml)>Ⅱb期(6.62±3.43 pg／ml)
结论：
1)正常人、CIN及宫颈癌患者的血清IL-6水平经过比较,差异有统计学意义,且与临床分期和CIN分级呈正相关；而IL-18和IFN-γ的水平则与临床分期和CIN分级呈现负相关。
2)不同临床病理分期宫颈癌患者的血清IL-6、IL-18及IFN-γ的水平也有所差异：临床分期越高,IL-6的水平越高,而IL-18和IFN-γ的水平却越低,说明IL-6、IL-18、IFN-γ与临床分期有一定的关系。
3)正常人、CIN及宫颈癌患者的血清IL-6与IL-18、IFN-γ水平存在负相关,而IL-18与IFN-γ水平存在显著正相关。
Objective:To investigate the level of IL-6、IL-18 and IFN-γin cervical squamous cell carcinomas, and seek reliable laboratory datas for clinical diagnosis and prognosis of cervical cancer.
Methods:Serum samples including 49 cases of squamous cell carcinomas(ICC),38 cases of cervical intraepithelial neoplasia and 18 cases of normal cervical tissues (NCE) were studied.Using Sandwich-Elisa technique, the author examined the level of IL-6、IL-18 and IFN-γin these samples.
Results:
1. Normal, CIN and cervical cancer group's IL-6 level were 13.42±2.14pg/ml,25.25±4.19pg/ml,57.15±13.22pg/ml, respectively. And the level of IL-6 in cervical cancer group was higher than the CIN group and the normal group (p<0.05), CIN group were also higher than the normal group (p<0.05). In different clinical stage of cervical cancer, IL-6 levels showed a rising trend.Ⅱb (59±13.22) pg/ml>Ⅱa (55.15±15.92) pg/ml>Ⅰa (42.15±11.42) pg/ml. When postoperative, the level of IL-6 in cervical cancer patients were significantly decreased compared with preoperative, (57.15±13.22pg/ml to 12.82±2.73pg/ml). The difference was both significant(P<0.05).
2. Normal, CIN and cervical cancer group's IL-18 level were 569.83±97.29 pg/ml、381.63±62.54pg/ml、252.65±52.81pg/ml, respectively. And the level of IL-18 in cervical cancer group was lower than the CIN group and the normal group (p<0.05), CIN group were also lower than the normal group (p<0.05). In different clinical stage of cervical cancer, IL-18 levels showed a decreasing trend.Ⅰa (628.84±89.62 pg/ml)>Ⅰb (539.81±78.19pg/ml)>Ⅱa(424.84±71.92pg/ml)>Ⅱb(401.25±72.37pg/ml. When postoperative,the level of IL-18 in cervical cancer patients were significantly increased compared with preoperative, (308.61±63.27 pg/ml to 569.83±97.29pg/ml) (p<0.01), (7.62±3.23pg/ml to 78.21±32.81pg/ml) The difference was both significant (p<0.05)
3. Normal, CIN and cervical cancer group's IFN-γlevel were 67.73±26.71pg/ml、23.94±15.74pg/ml、7.62±3.23pg/mlrespectively. And the level of IFN-γin cervical cancer group was lower than the CIN group and the normal group (p<0.05), CIN group were also lower than the normal group (p<0.05). In different clinical stage of cervical cancer, IFN-Y levels showed a decreasing trend.Ⅰa (12.81±4.03 pg/ml)>Ⅰb (9.32±3.83 pg/ml)>Ⅱa (8.82±2.93 pg/ml)>Ⅱb (6.62±3.43 pg/ml)
Conclusion:
1. The high level of IL-6 and the low level of IL-18 and IFN-γin cervical carcinoma might be correlated with invasive behavior of cervical carcinoma. They might become useful Prognostic and diagnosis indicators for early cervical carcinoma.
2. Different clinical parameters of serum IL-6, IL-18 and IFN-γlevels also difference in cervical cancer patients; The high clinical stage, the high IL-6 levels, then the levels of IL-18 and IFN-γare lower. It means that level of IL-6, IL-18, IFN-γhave some relationship with the clinical stage of cervical cancer.
3. There was no correlation between IL-6 and IL-18 in invasive cervical careinoma, and there was a negative correlation between IL-6 and IFN-Y.also the positive correlation between IL-18 and IFN-γ.
方法：本研究采用夹心酶联免疫吸附法测定18例正常人、38例宫颈上皮内瘤变(CIN)患者及49例宫颈癌患者血清中IL-6、IL-18及IFN-γ的水平。
结果：
1、正常组、CIN组及宫颈癌组中IL-6的水平分别为13.42±2.14pg／ml、25.25±4.19pg／ml、57.15±13.22pg／ml,其中宫颈癌组IL-6的水平高于CIN及正常组(p<0.05),CIN组也高于正常组(p<0.05).在宫颈癌的不同临床期别中,IL-6的水平呈现出上升的趋势,IL-6的水平是随的宫颈癌临床期别的升高而增加的,Ⅱb期59±13.22pg／ml>Ⅱa期55.15±15.92pg／ml>Ⅰa期42.15±11.42 pg／ml
2、正常组、CIN组及宫颈癌组中IL-18的水平分别为569.83±97.29 pg／ml、381.63±62.54pg／ml、252.65±52.81pg／ml,其中宫颈癌组IL-18的水平低于CIN及正常组(p<0.05),CIN组也低于正常组(p<0.05).IL-18的水平则随着临床期别的升高而下降,Ⅰa期(628.84±89.62 pg／ml)>Ⅰb期(539.81±78.19)>Ⅱa期(424.84±71.92)>Ⅱa期(424.84±71.92)Ⅱb期(424.84±71.92
3、正常组、CIN组及宫颈癌组中IFN-γ的水平分别为67.73±26.71pg／ml、23.94±15.74pg／ml、7.62±3.23pg／ml,其中宫颈癌组IFN-γ的水平明显低于正常组(p<0.01),CIN组也低于正常组(p<0.05),IFN-γ水平随着临床期别的升高,水平也有下降的趋势,Ⅰa期(12.81±4.03 pg／ml)>Ⅰb期(9.32±3.83pg／ml)>Ⅱa期(8.82±2.93 pg／ml)>Ⅱb期(6.62±3.43 pg／ml)
结论：
1)正常人、CIN及宫颈癌患者的血清IL-6水平经过比较,差异有统计学意义,且与临床分期和CIN分级呈正相关；而IL-18和IFN-γ的水平则与临床分期和CIN分级呈现负相关。
2)不同临床病理分期宫颈癌患者的血清IL-6、IL-18及IFN-γ的水平也有所差异：临床分期越高,IL-6的水平越高,而IL-18和IFN-γ的水平却越低,说明IL-6、IL-18、IFN-γ与临床分期有一定的关系。
3)正常人、CIN及宫颈癌患者的血清IL-6与IL-18、IFN-γ水平存在负相关,而IL-18与IFN-γ水平存在显著正相关。
Objective:To investigate the level of IL-6、IL-18 and IFN-γin cervical squamous cell carcinomas, and seek reliable laboratory datas for clinical diagnosis and prognosis of cervical cancer.
Methods:Serum samples including 49 cases of squamous cell carcinomas(ICC),38 cases of cervical intraepithelial neoplasia and 18 cases of normal cervical tissues (NCE) were studied.Using Sandwich-Elisa technique, the author examined the level of IL-6、IL-18 and IFN-γin these samples.
Results:
1. Normal, CIN and cervical cancer group's IL-6 level were 13.42±2.14pg/ml,25.25±4.19pg/ml,57.15±13.22pg/ml, respectively. And the level of IL-6 in cervical cancer group was higher than the CIN group and the normal group (p<0.05), CIN group were also higher than the normal group (p<0.05). In different clinical stage of cervical cancer, IL-6 levels showed a rising trend.Ⅱb (59±13.22) pg/ml>Ⅱa (55.15±15.92) pg/ml>Ⅰa (42.15±11.42) pg/ml. When postoperative, the level of IL-6 in cervical cancer patients were significantly decreased compared with preoperative, (57.15±13.22pg/ml to 12.82±2.73pg/ml). The difference was both significant(P<0.05).
2. Normal, CIN and cervical cancer group's IL-18 level were 569.83±97.29 pg/ml、381.63±62.54pg/ml、252.65±52.81pg/ml, respectively. And the level of IL-18 in cervical cancer group was lower than the CIN group and the normal group (p<0.05), CIN group were also lower than the normal group (p<0.05). In different clinical stage of cervical cancer, IL-18 levels showed a decreasing trend.Ⅰa (628.84±89.62 pg/ml)>Ⅰb (539.81±78.19pg/ml)>Ⅱa(424.84±71.92pg/ml)>Ⅱb(401.25±72.37pg/ml. When postoperative,the level of IL-18 in cervical cancer patients were significantly increased compared with preoperative, (308.61±63.27 pg/ml to 569.83±97.29pg/ml) (p<0.01), (7.62±3.23pg/ml to 78.21±32.81pg/ml) The difference was both significant (p<0.05)
3. Normal, CIN and cervical cancer group's IFN-γlevel were 67.73±26.71pg/ml、23.94±15.74pg/ml、7.62±3.23pg/mlrespectively. And the level of IFN-γin cervical cancer group was lower than the CIN group and the normal group (p<0.05), CIN group were also lower than the normal group (p<0.05). In different clinical stage of cervical cancer, IFN-Y levels showed a decreasing trend.Ⅰa (12.81±4.03 pg/ml)>Ⅰb (9.32±3.83 pg/ml)>Ⅱa (8.82±2.93 pg/ml)>Ⅱb (6.62±3.43 pg/ml)
Conclusion:
1. The high level of IL-6 and the low level of IL-18 and IFN-γin cervical carcinoma might be correlated with invasive behavior of cervical carcinoma. They might become useful Prognostic and diagnosis indicators for early cervical carcinoma.
2. Different clinical parameters of serum IL-6, IL-18 and IFN-γlevels also difference in cervical cancer patients; The high clinical stage, the high IL-6 levels, then the levels of IL-18 and IFN-γare lower. It means that level of IL-6, IL-18, IFN-γhave some relationship with the clinical stage of cervical cancer.
3. There was no correlation between IL-6 and IL-18 in invasive cervical careinoma, and there was a negative correlation between IL-6 and IFN-Y.also the positive correlation between IL-18 and IFN-γ.
引文
[1]Schiffman, M. et al. A Population-Based Prospective Study of Carcinogenic Human Papillomavirus Variant Lineages, Viral Persistence, and Cervical Neoplasia. Cancer Res,2010.
[2]Federico C, Alleyn J, Dola Cet al. Relationship among age, race, medical funding, and cervical cancer survival. [J] J Natl Med Assoc. 2010. Mar,102(3):199-205.
[3]Tan, C, et al., Modeling the Relationship Between Cervical Cancer Mortality and Trace Elements Based on Genetic Algorithm-Partial Least Squares and Support Vector Machines. [J] Biol Trace Elem Res,2010 Mar;102(3):199-205.
[4]Rusiecka M, Alleyn J, Dola C, et al.The value of the cytocins and the solubility of theirs receptors in the serum of the patients with the cervical cancer.[J] Ginekol Pol.2007 Sep;78(9):691-5.
[5]Tan, C., et al. Modeling the Relationship Between Cervical Cancer Mortality and Trace Elements Based on Genetic Algorithm-Partial Least Squares and Support Vector Machines. Biol Trace Elem Res,2010.
[6]Gangwar R, Mittal B, Mittal RD. Association of interleukin-6-174G>C promoter polymorphism with risk of cervical cancer. [J] Int J Biol Markers. 2009 Jan-Mar;24(1):11-6.
[7]Sobti RC, Shekari M, Tamandani DM, et al. Association of interleukin-18 gene promoter polymorphism on the risk of cervix carcinogenesis in north Indian population. [J]Oncol Res.2008;17(4):159-66.
[8]Kang YH, Lee KA, Yang Y, et al.The apop totic effect of intercalating agents on HPV-negative cervical cancer C-33A cells[J].Am ino Acids,2007,33:105-112
[9]Gray PW, Goeddel DV. Structure of the human immune interferon gene. [J]Nature.1982 Aug 26;298(5877):859-63.
[10]Ealick SE, et al., Three-dimensional structure of recombinant human interferon-gamma. [J]Science.1991 May 3;252(5006):698-702.
[11]Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma:an overview of signals, mechanisms and functions. [J]J Leukoc Biol.2004 Feb; 75 (2):163-89.
[12]Gangwar R, Pandey S, Mittal RD. Association of interferon-gamma+874A polymorphism with the risk of developing cervical cancer in north-Indian population. [J] BJOG.2009 Nov;116(12):1671-7. Epub 2009 Aug 14.
[13]Han JE, Kim HK, Park SA, et al. A nontoxic derivative of lipopolysaccharide increases immune responses to Gardasil HPV vaccine in mice. [J]Int Immunopharmacol.2010 Feb;10(2):169-76. Epub 2009 Oct 28.
[14]Sharma A, Rajappa M, Satyam A et al. Cytokines (TH1 and TH2) in patients with advanced cervical cancer undergoing neoadjuvant chemoradiation:correlation with treatment response. [J]Int J Gynecol Cancer.2009 Oct;19(7):1269-75.
[15]Ding Y, Seow SV, Huang CH,et al. Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity. [J]Immunology.2009 Sep;128(1 Suppl):e881-94. Epub 2009 Mar 26.
[16]Bais AG, Beckmann I, Lindemans J, et al. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions [J].J Clin Pathol, 2005,58(10):1096-1100.
[17]S.-H. Song et al. Interferon-γ (IFN-γ):A possible prognostic marker for clearance of high-risk human papillomavirus (HPV). Gynecologic Oncology 108 (2008):543-548.
[18]Scott, M. E., et al. Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. Int J Cancer, 2009.124(6):p.1379-83.
[19]Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, Miller S, Canjura-Clayton KL, Farhat S, Broering JM, Darragh TM. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004:364:1678-83.
[20]Cooper K, Evans M, Mount S. Biology and evolution of cervical squamous intraepithelial lesions:a hypothesis with diagnostic prognostic implications. Adv Anat Pathol 2003;10:200-3.
[21]Castrilli G, Tatone D, Di odoro MG, et al. Interluekin 1-alpha and Interluekin-6 promote the in vitro growth of both normol and neoplastic human cervical epithelial cells [J]. Br J Cancer,1997,75(6):855-859.
[22]Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, et al. Interleukin-6 in cervical cancer:the relationship with vascular endothelial growth factor. Gynecol Oncol 2001;82(1):49-56.
[23]Fjiong MY, van der Vange N, ten Kate FJ, et al. Increased IL-6 and IL-8 levels in cervieovaginal secretions of patients with cervical cancer. Gynecol Onco 1.1999.73(2):285-291.
[24]Srivani R, Nagurajan B. A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer lnt J Gvnecol Cancer.2003.13(3):331-339.
[25]J. Alast air Gracie. Susan E. Robertson et al. Interleukin-18. Journal of Leukocyte Biology,2003,73:213.
[26][Lee K A, Cho K J, Kim S H, et al. IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on the IL-19-mediated immune response [J]. Cancer Lett,2005,229(2):261-270.
[27]Cho YS, Kang JW, Cho M et al. Down modulation of IL-18 expression by human papillomav irus type 16 E6 oncogene via binding to IL-18. FEBS Lett,2001,501(2-3):139.
[28]Matsubara S, Takeda K, Kodama T, et al. IL-2 and IL-18 attenuation of airway hyperresponsiveness requires STAT4, IFN-gamma, and natural killer cells. [J]. Am J Respir Cell Mol Biol,2007,36(3):324-332.
[29]元涛,王前,郑磊,等.IL-18基因启动子单核苷酸多态性及血清水平与宫颈癌相关性[J].南方医科大学学报,2008,28：754-757.
[30]Kang YH, Lee KA, Yang Y, et al. The apoptotic effect of intercalating agents on HPV-negative cervical cancer C33A cells [J]. Amino Acids,2007, 33:1052112.
[31]Zhang B, Wu K F, Cao Z Y, et al. IL-18 incr eases invasiveness of HL-60 myeloid leukemia cells:up-regulation of matrix metallo-proteinases-9(MMP-9)expression[J]. Leuk Res,2004,28(1):91-95.
[32]Micallef M J, Yoshida K, Kawai S, et al. In vivo antitumor effects of murine interferon-r-indu cing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascite s[J]. Cancer Immunol lmmunotber,1997,43 (6):361-367.
[33]Qi, T, Wang, Q, Zheng, L, Yang, H L, Bao, J. [Correlation of serum IL-18 level and IL-18 gene promoter polymorphisms to the risk of cervical cancer]. Nan Fang Yi Ke Da Xue Xue Bao,2008.28(5):754-7.
[34]Matsubara S, Takeda K, Kodama T, et al. IL-2 and IL-18 attenuation of airway hyperresponsiveness requires STAT4, IFN-gamma, and natural killer cells. [J]. Am J Respir Cell Mol Biol,2007,36(3):324-332.
[35]Kawabata T, Lehikura T, Mahima T, et al. Preopratative serum IL-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer,2001,92 (8):2050-2055.
[36]Mendoza L, Carrascal T, De Luca AM, et al. Hydrogen peroxide mediates vascular cell adhesion molecule-1 expression from interleukon-18-activated hepatic sinusoidal endothelium:implications for circulating cancer cell arrest in the murine liver. Hepatology,2001,34 (2):298-310.
[37]蒋代凤,刘万里,陆应麟,等.1L-18促进肺癌细胞转移的功能鉴定.中华肿瘤杂志,2003,25(4)：348-352.
[38]Lee, K A, Cho, K J, Kim, S H Shim, J H, Lim, J S, Cho, D H, Song, M S, Dinarello, C A, Yoon, D Y. IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on the IL-18-mediated immune response. Cancer Lett,2005.229(2):261-70.
[39]郑九生,杜二球,周小飞,刘淮,张红玲,张桂芳新生儿IL-18对Th1／Th2类细胞免疫平衡的作用与HBV宫内感染相关性研究.
[40]Govan VA, Carrara HR, Sachs JA, Hoffman M, Stanczuk GA, Williamson AL. Ethnic differences in allelic distribution of IFN-γ in South African women but no link with cervical cancer. J Carcinog 2003;2(1):3.
[41]Karmakar S, Dhar R, Das C. Inhibition of cytotrophoblastic(JEG-3)cell invasion by interleukin 12 involves an interferon gamma-mediated pathway. J Biol Chem 2004:279:55297-307
[42]Van Nimwegen MJ, van de Water B. Focal adhesion kinase:a potential target in cancer therapy. Biochem Pharmacol 2007;73:597-609.
[43]Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells.Curr Opin Cell Biol 2006; 18:516-23.
[44]Scott M, Stites DP, Moscicki AB. Thl cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol 1999;6(5):751-5.
[45]CD3 ζ Expression and T Cell Proliferation are Inhibited by TGF-β1 and IL-10 in Cervical Cancer Patients.2009
[46]Association of interferon-c +874A polymorphism with the risk of developing cervical cancer in north-Indian population,2009
[47]YoshidaH, Katayose, UnnoM, SuzukiM, KodamaH, TakemuraS, Asano R, HayashiH, YamamotoK, MatsunoS, KudoT. Anoveladeno virus expressing human4-IBB ligandenhances antitumorimmunity. Cancer Immunol Immunother 2003:52:97-106.
[48]Gollob JA, Sciambi CJ, Huang Z, Dressman HK. Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. Cancer Res 2005;65:8869-77.
[49]Lai HC, Chang CC, Lin YW, Chen SF, Yu MH, Nieh S, et al. Genetic polymorphism of the interferon-gamma gene in cervical carcinogenesis. Int J Cancer 2005;113(5):712-8.
[50]Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001;8(2):209-20.
[51]Song SH, Lee JK, Seok OS, Saw HS. The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix. Gynecol Oncol 2007;104(3):732-8.
[52]Kang YH, Lee KA, Ryu CJ, et al. Mitomycin C induces apoptosis via Fas/FasL dependent pathway and suppression of IL-18 in cervical carcinoma cells[J]. Cancer Lett,2006,237(1):33-44.
[53]Nakanishi K, Yoshimoto T, Tsutsui H, et al. Interleukin-18 is a unique cytokine that stimulates both Thl and Th2 responses depending on its cytokine milieu [J]. Cytokine Growth Gactor Rev,2001,12:53-72.
[54]Kohno K, Kataoka T, Ohtsuki Y, et al. IFN-c-inducing factor(IGIF)is a costimulatory factor on the activation of Thl but not Th2 cells and exerts its effect independently of IL-12.J Immunol 1997:158:1541-1550.
[55]Naka T,Nishimoto N, Kishimoto T. The paradigm of IL-6:from basic science to medicine. Arthritis Res 2002;4:233-242.
[56]Osaki T, Peron JM, Cai Q, et al.IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma-and IL-12-independent antitumor effects [J]. J Immunol,1998,160(4):1742-1749.
[2]Federico C, Alleyn J, Dola Cet al. Relationship among age, race, medical funding, and cervical cancer survival. [J] J Natl Med Assoc. 2010. Mar,102(3):199-205.
[3]Tan, C, et al., Modeling the Relationship Between Cervical Cancer Mortality and Trace Elements Based on Genetic Algorithm-Partial Least Squares and Support Vector Machines. [J] Biol Trace Elem Res,2010 Mar;102(3):199-205.
[4]Rusiecka M, Alleyn J, Dola C, et al.The value of the cytocins and the solubility of theirs receptors in the serum of the patients with the cervical cancer.[J] Ginekol Pol.2007 Sep;78(9):691-5.
[5]Tan, C., et al. Modeling the Relationship Between Cervical Cancer Mortality and Trace Elements Based on Genetic Algorithm-Partial Least Squares and Support Vector Machines. Biol Trace Elem Res,2010.
[6]Gangwar R, Mittal B, Mittal RD. Association of interleukin-6-174G>C promoter polymorphism with risk of cervical cancer. [J] Int J Biol Markers. 2009 Jan-Mar;24(1):11-6.
[7]Sobti RC, Shekari M, Tamandani DM, et al. Association of interleukin-18 gene promoter polymorphism on the risk of cervix carcinogenesis in north Indian population. [J]Oncol Res.2008;17(4):159-66.
[8]Kang YH, Lee KA, Yang Y, et al.The apop totic effect of intercalating agents on HPV-negative cervical cancer C-33A cells[J].Am ino Acids,2007,33:105-112
[9]Gray PW, Goeddel DV. Structure of the human immune interferon gene. [J]Nature.1982 Aug 26;298(5877):859-63.
[10]Ealick SE, et al., Three-dimensional structure of recombinant human interferon-gamma. [J]Science.1991 May 3;252(5006):698-702.
[11]Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma:an overview of signals, mechanisms and functions. [J]J Leukoc Biol.2004 Feb; 75 (2):163-89.
[12]Gangwar R, Pandey S, Mittal RD. Association of interferon-gamma+874A polymorphism with the risk of developing cervical cancer in north-Indian population. [J] BJOG.2009 Nov;116(12):1671-7. Epub 2009 Aug 14.
[13]Han JE, Kim HK, Park SA, et al. A nontoxic derivative of lipopolysaccharide increases immune responses to Gardasil HPV vaccine in mice. [J]Int Immunopharmacol.2010 Feb;10(2):169-76. Epub 2009 Oct 28.
[14]Sharma A, Rajappa M, Satyam A et al. Cytokines (TH1 and TH2) in patients with advanced cervical cancer undergoing neoadjuvant chemoradiation:correlation with treatment response. [J]Int J Gynecol Cancer.2009 Oct;19(7):1269-75.
[15]Ding Y, Seow SV, Huang CH,et al. Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity. [J]Immunology.2009 Sep;128(1 Suppl):e881-94. Epub 2009 Mar 26.
[16]Bais AG, Beckmann I, Lindemans J, et al. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions [J].J Clin Pathol, 2005,58(10):1096-1100.
[17]S.-H. Song et al. Interferon-γ (IFN-γ):A possible prognostic marker for clearance of high-risk human papillomavirus (HPV). Gynecologic Oncology 108 (2008):543-548.
[18]Scott, M. E., et al. Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. Int J Cancer, 2009.124(6):p.1379-83.
[19]Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, Miller S, Canjura-Clayton KL, Farhat S, Broering JM, Darragh TM. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004:364:1678-83.
[20]Cooper K, Evans M, Mount S. Biology and evolution of cervical squamous intraepithelial lesions:a hypothesis with diagnostic prognostic implications. Adv Anat Pathol 2003;10:200-3.
[21]Castrilli G, Tatone D, Di odoro MG, et al. Interluekin 1-alpha and Interluekin-6 promote the in vitro growth of both normol and neoplastic human cervical epithelial cells [J]. Br J Cancer,1997,75(6):855-859.
[22]Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, et al. Interleukin-6 in cervical cancer:the relationship with vascular endothelial growth factor. Gynecol Oncol 2001;82(1):49-56.
[23]Fjiong MY, van der Vange N, ten Kate FJ, et al. Increased IL-6 and IL-8 levels in cervieovaginal secretions of patients with cervical cancer. Gynecol Onco 1.1999.73(2):285-291.
[24]Srivani R, Nagurajan B. A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer lnt J Gvnecol Cancer.2003.13(3):331-339.
[25]J. Alast air Gracie. Susan E. Robertson et al. Interleukin-18. Journal of Leukocyte Biology,2003,73:213.
[26][Lee K A, Cho K J, Kim S H, et al. IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on the IL-19-mediated immune response [J]. Cancer Lett,2005,229(2):261-270.
[27]Cho YS, Kang JW, Cho M et al. Down modulation of IL-18 expression by human papillomav irus type 16 E6 oncogene via binding to IL-18. FEBS Lett,2001,501(2-3):139.
[28]Matsubara S, Takeda K, Kodama T, et al. IL-2 and IL-18 attenuation of airway hyperresponsiveness requires STAT4, IFN-gamma, and natural killer cells. [J]. Am J Respir Cell Mol Biol,2007,36(3):324-332.
[29]元涛,王前,郑磊,等.IL-18基因启动子单核苷酸多态性及血清水平与宫颈癌相关性[J].南方医科大学学报,2008,28：754-757.
[30]Kang YH, Lee KA, Yang Y, et al. The apoptotic effect of intercalating agents on HPV-negative cervical cancer C33A cells [J]. Amino Acids,2007, 33:1052112.
[31]Zhang B, Wu K F, Cao Z Y, et al. IL-18 incr eases invasiveness of HL-60 myeloid leukemia cells:up-regulation of matrix metallo-proteinases-9(MMP-9)expression[J]. Leuk Res,2004,28(1):91-95.
[32]Micallef M J, Yoshida K, Kawai S, et al. In vivo antitumor effects of murine interferon-r-indu cing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascite s[J]. Cancer Immunol lmmunotber,1997,43 (6):361-367.
[33]Qi, T, Wang, Q, Zheng, L, Yang, H L, Bao, J. [Correlation of serum IL-18 level and IL-18 gene promoter polymorphisms to the risk of cervical cancer]. Nan Fang Yi Ke Da Xue Xue Bao,2008.28(5):754-7.
[34]Matsubara S, Takeda K, Kodama T, et al. IL-2 and IL-18 attenuation of airway hyperresponsiveness requires STAT4, IFN-gamma, and natural killer cells. [J]. Am J Respir Cell Mol Biol,2007,36(3):324-332.
[35]Kawabata T, Lehikura T, Mahima T, et al. Preopratative serum IL-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer,2001,92 (8):2050-2055.
[36]Mendoza L, Carrascal T, De Luca AM, et al. Hydrogen peroxide mediates vascular cell adhesion molecule-1 expression from interleukon-18-activated hepatic sinusoidal endothelium:implications for circulating cancer cell arrest in the murine liver. Hepatology,2001,34 (2):298-310.
[37]蒋代凤,刘万里,陆应麟,等.1L-18促进肺癌细胞转移的功能鉴定.中华肿瘤杂志,2003,25(4)：348-352.
[38]Lee, K A, Cho, K J, Kim, S H Shim, J H, Lim, J S, Cho, D H, Song, M S, Dinarello, C A, Yoon, D Y. IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on the IL-18-mediated immune response. Cancer Lett,2005.229(2):261-70.
[39]郑九生,杜二球,周小飞,刘淮,张红玲,张桂芳新生儿IL-18对Th1／Th2类细胞免疫平衡的作用与HBV宫内感染相关性研究.
[40]Govan VA, Carrara HR, Sachs JA, Hoffman M, Stanczuk GA, Williamson AL. Ethnic differences in allelic distribution of IFN-γ in South African women but no link with cervical cancer. J Carcinog 2003;2(1):3.
[41]Karmakar S, Dhar R, Das C. Inhibition of cytotrophoblastic(JEG-3)cell invasion by interleukin 12 involves an interferon gamma-mediated pathway. J Biol Chem 2004:279:55297-307
[42]Van Nimwegen MJ, van de Water B. Focal adhesion kinase:a potential target in cancer therapy. Biochem Pharmacol 2007;73:597-609.
[43]Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells.Curr Opin Cell Biol 2006; 18:516-23.
[44]Scott M, Stites DP, Moscicki AB. Thl cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol 1999;6(5):751-5.
[45]CD3 ζ Expression and T Cell Proliferation are Inhibited by TGF-β1 and IL-10 in Cervical Cancer Patients.2009
[46]Association of interferon-c +874A polymorphism with the risk of developing cervical cancer in north-Indian population,2009
[47]YoshidaH, Katayose, UnnoM, SuzukiM, KodamaH, TakemuraS, Asano R, HayashiH, YamamotoK, MatsunoS, KudoT. Anoveladeno virus expressing human4-IBB ligandenhances antitumorimmunity. Cancer Immunol Immunother 2003:52:97-106.
[48]Gollob JA, Sciambi CJ, Huang Z, Dressman HK. Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. Cancer Res 2005;65:8869-77.
[49]Lai HC, Chang CC, Lin YW, Chen SF, Yu MH, Nieh S, et al. Genetic polymorphism of the interferon-gamma gene in cervical carcinogenesis. Int J Cancer 2005;113(5):712-8.
[50]Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001;8(2):209-20.
[51]Song SH, Lee JK, Seok OS, Saw HS. The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix. Gynecol Oncol 2007;104(3):732-8.
[52]Kang YH, Lee KA, Ryu CJ, et al. Mitomycin C induces apoptosis via Fas/FasL dependent pathway and suppression of IL-18 in cervical carcinoma cells[J]. Cancer Lett,2006,237(1):33-44.
[53]Nakanishi K, Yoshimoto T, Tsutsui H, et al. Interleukin-18 is a unique cytokine that stimulates both Thl and Th2 responses depending on its cytokine milieu [J]. Cytokine Growth Gactor Rev,2001,12:53-72.
[54]Kohno K, Kataoka T, Ohtsuki Y, et al. IFN-c-inducing factor(IGIF)is a costimulatory factor on the activation of Thl but not Th2 cells and exerts its effect independently of IL-12.J Immunol 1997:158:1541-1550.
[55]Naka T,Nishimoto N, Kishimoto T. The paradigm of IL-6:from basic science to medicine. Arthritis Res 2002;4:233-242.
[56]Osaki T, Peron JM, Cai Q, et al.IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma-and IL-12-independent antitumor effects [J]. J Immunol,1998,160(4):1742-1749.